Annovis Bio, Inc.
NYSE:ANVSBiotechnology
Healthcare
$1.21 +0.00%
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
52W Low $1.54High $5.50
Volume 1.35M
Average 1.08M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$25.62B
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$34.60B
FY 2025 · Annual
+29.6% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (14.49M) | (25.33M) | (56.2M) | (24.59B) | (28.85B) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.7M | 9.15M | 4.63M | 3.84B | 1.8B |
| Change in Working Capital | 657.35K | (1.14M) | (228.6K) | 681.71K | 1.58M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 346.22K | 3.27M | (2.67M) | 1.01M | 284.54K |
| Other Working Capital | 311.13K | (4.41M) | 2.44M | (331.43K) | 1.29M |
| Other Non-Cash Items | 0 | 0 | 11.84M | (1.14B) | 1.44B |
| Operating Cash Flow | (9.13M) | (17.31M) | (39.97M) | (21.89B) | (25.62B) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 46.65M | 4.61K | 16.89M | 18.67M | 34.6M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 95.1K | 0 | 458.39K | 26.67B | 34.57B |
| Financing Cash Flow | 46.74M | 4.61K | 17.34M | 26.69B | 34.6B |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.61M | (17.31M) | (22.62M) | 4.8B | 8.98B |
| Free Cash Flow | (9.13M) | (17.31M) | (39.97M) | (21.89B) | (25.62B) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$28.9B
+ D&A$0
+ Stock-Based Comp$1.8B
+ Deferred Tax$0
+ Working Capital$1.6M
+ Other Non-Cash$1.4B
= Operating Cash Flow-$25.6B
- Capex$0
= Free Cash Flow-$25.6B
Analysis
FY2025 free cash flow is -$25.6B. FCF conversion is 88.8% of net income. Operating cash flow was -$25.6B, with capex of $0. The largest bridge item is Stock-Based Comp at $1.8B.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| DEF 14A | DEF 14A filing | Sep 11, 2026 | |
| PRE 14A | PRE 14A filing | Aug 25, 2026 | |
| 10-Q | Quarterly report | Aug 14, 2026 | |
| SC 13G | SC 13G filing | Aug 14, 2026 | |
| 8-K | Current report | Aug 14, 2026 |
Does ANVS generate free cash flow?
Annovis Bio, Inc. (ANVS) generated -$25.62B of free cash flow in fiscal 2025.
How much operating cash flow does ANVS produce?
Operating cash flow was -$25.62B, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.